Genetic variant near cytosolic phospholipase A(2) associated with schizophrenia

被引：71

作者：

Hudson, CJ

Kennedy, JL

Gotowiec, A

Lin, A

King, N

Gojtan, K

Macciardi, F

Skorecki, K

Meltzer, HY

Warsh, JJ

Horrobin, DF

机构：

[1] CLARKE INST PSYCHIAT, SCHIZOPHRENIA PROGRAM, TORONTO, ON M5T 1R8, CANADA

[2] HOSP SAN RAFFAELE, DIPARTIMENTO SCI NEUROPSICHICHE, I-20127 MILAN, ITALY

[3] HOSP SICK CHILDREN, DIV NEPHROL, TORONTO, ON M5G 1X8, CANADA

[4] CASE WESTERN RESERVE UNIV, DEPT PSYCHIAT, CLEVELAND, OH 44106 USA

[5] SCOTIA PHARMACEUT LTD, GUILDFORD GU1 1BA, SURREY, ENGLAND

来源：

SCHIZOPHRENIA RESEARCH | 1996年 / 21卷 / 02期

基金：

英国医学研究理事会;

关键词：

phospholipase A(2); genetic polymorphism; haplotype relative risk; genetic association; schizophrenia;

D O I：

10.1016/0920-9964(96)00031-X

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Two studies were undertaken to determine a possible genetic basis for alterations in phospholipid metabolism in schizophrenia. Initial results demonstrated an association in 65 schizophrenics compared with a matched normal control population. A follow-up haplotype relative risk study of 44 triads (mother, father, affected offspring), confirmed the results seen in the association study. Results suggest that a genetic variant near the promotor region of the gene for cytosolic phospholipase A(2), the rate-limiting enzyme in the synthesis of prostaglandins from arachidonic acid, is associated with schizophrenia.

引用

页码：111 / 116

页数：6

共 36 条

[1] THE CURRENT STATUS OF THE DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA [J].